- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.11. | FDA halts uniQure's plans for Huntington's disease gene therapy | ||
| 04.11. | Tidmarsh's FDA exit marks latest high-profile jockeying at US agencies | ||
| 04.11. | Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn | ||
| 04.11. | FDA approves UCB's Kygevvi for genetic mitochondrial disease | ||
| 04.11. | Eli Lilly to invest $3bn in new Dutch manufacturing facility | ||
| 04.11. | Alvotech faces FDA setback for its Simponi biosimilar AVT05 | ||
| 03.11. | Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war | ||
| 03.11. | IntoCell and Xcellon Biologics to advance ADC development | ||
| 03.11. | 4DMT and Otsuka to advance eye disease treatment in APAC | ||
| 31.10. | Sensei to ditch its lead candidate and cut workforce amidst strategic review | ||
| 31.10. | Massive sales for weight loss drugs spur Eli Lilly's Q3 | ||
| 31.10. | Debiopharm and NetTargets to identify synergistic drug combos for ADCs | ||
| 31.10. | Helex secures $3.5m to advance kidney disease therapies | ||
| 30.10. | Health Canada grants NOC for AstraZeneca's breast cancer therapy | ||
| 30.10. | FDA looks to simplify biosimilar development with new draft guidance | ||
| 30.10. | Novo Nordisk locks horns with Pfizer in late bid for Metsera | ||
| 30.10. | Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion | ||
| 30.10. | Dewpoint receives FDA orphan drug designation for DPTX3186 | ||
| 30.10. | Seres to obtain $3.6m from CARB-X for SER-155 development | ||
| 29.10. | Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis | ||
| 29.10. | Eli Lilly and NVIDIA to build pharma's "most powerful" supercomputer | ||
| 29.10. | CPHI 2025: time for European biopharma to double down on innovation | ||
| 29.10. | FDA rejects Regeneron's pre-filled Eylea HD syringes amid filling facility woes | ||
| 29.10. | GSK forges pact with Empirico for respiratory siRNA in $745m deal | ||
| 29.10. | Aldeyra reshuffles pipeline, culling asset despite Phase II success |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .